UNLABELLED: A more thorough understanding of the genetic architecture underlying obesity-related lipid disorders could someday facilitate cardiometabolic risk reduction through early clinical intervention based upon improved characterization of individual risk. In recent years, there has been tremendous interest in understanding the endocannabinoid system as a novel therapeutic target for the treatment of obesity-related dyslipidemia. AIMS: N-arachidonylethanolamine activates G-protein-coupled receptors within the endocannabinoid system. Fatty acid amide hydrolase (FAAH) is a primary catabolic regulator of N-acylethanolamines, including arachidonylethanolamine. Genetic variants in FAAH have inconsistently been associated with obesity. It is conceivable that genetic variability in FAAH directly influences lipid homeostasis. The current study characterizes the relationship between FAAH and obesity-related dyslipidemia, in one of the most rigorously-phenotyped obesity study cohorts in the USA. MATERIALS & METHODS: Members of 261 extended families (pedigrees ranging from 4 to 14 individuals) were genotyped using haplotype tagging SNPs obtained for the FAAH locus, including 5 kb upstream and 5 kb downstream. Each SNP was tested for basic obesity-related phenotypes (BMI, waist and hip circumference, waist:hip ratio, fasting glucose, fasting insulin and fasting lipid levels) in 1644 individuals within these 261 families. Each SNP was also tested for association with insulin responsiveness using data obtained from a frequently sampled intravenous glucose tolerance test in 399 individuals (32 extended families). RESULTS: A well characterized coding SNP in FAAH (rs324420) was associated with increased BMI, increased triglycerides, and reduced levels of high-density lipoprotein cholesterol. Mean (standard deviation) high-density lipoprotein cholesterol level was 40.5 (14.7) mg/dl for major allele homozygotes, 39.1 (10.4) mg/dl for heterozygotes, and 34.8 (8.1) mg/dl for minor allele homozygotes (p < 0.01, Family-Based Association Test). This SNP was not associated with insulin sensitivity, acute insulin response to intravenous glucose, glucose effectiveness or glucose disposition index. CONCLUSION: Genetic variability in FAAH is associated with dyslipidemia, independent of insulin response.
UNLABELLED: A more thorough understanding of the genetic architecture underlying obesity-related lipid disorders could someday facilitate cardiometabolic risk reduction through early clinical intervention based upon improved characterization of individual risk. In recent years, there has been tremendous interest in understanding the endocannabinoid system as a novel therapeutic target for the treatment of obesity-related dyslipidemia. AIMS: N-arachidonylethanolamine activates G-protein-coupled receptors within the endocannabinoid system. Fatty acid amide hydrolase (FAAH) is a primary catabolic regulator of N-acylethanolamines, including arachidonylethanolamine. Genetic variants in FAAH have inconsistently been associated with obesity. It is conceivable that genetic variability in FAAH directly influences lipid homeostasis. The current study characterizes the relationship between FAAH and obesity-related dyslipidemia, in one of the most rigorously-phenotyped obesity study cohorts in the USA. MATERIALS & METHODS: Members of 261 extended families (pedigrees ranging from 4 to 14 individuals) were genotyped using haplotype tagging SNPs obtained for the FAAH locus, including 5 kb upstream and 5 kb downstream. Each SNP was tested for basic obesity-related phenotypes (BMI, waist and hip circumference, waist:hip ratio, fasting glucose, fasting insulin and fasting lipid levels) in 1644 individuals within these 261 families. Each SNP was also tested for association with insulin responsiveness using data obtained from a frequently sampled intravenous glucose tolerance test in 399 individuals (32 extended families). RESULTS: A well characterized coding SNP in FAAH (rs324420) was associated with increased BMI, increased triglycerides, and reduced levels of high-density lipoprotein cholesterol. Mean (standard deviation) high-density lipoprotein cholesterol level was 40.5 (14.7) mg/dl for major allele homozygotes, 39.1 (10.4) mg/dl for heterozygotes, and 34.8 (8.1) mg/dl for minor allele homozygotes (p < 0.01, Family-Based Association Test). This SNP was not associated with insulin sensitivity, acute insulin response to intravenous glucose, glucose effectiveness or glucose disposition index. CONCLUSION: Genetic variability in FAAH is associated with dyslipidemia, independent of insulin response.
Authors: A H Kissebah; G E Sonnenberg; J Myklebust; M Goldstein; K Broman; R G James; J A Marks; G R Krakower; H J Jacob; J Weber; L Martin; J Blangero; A G Comuzzie Journal: Proc Natl Acad Sci U S A Date: 2000-12-19 Impact factor: 11.205
Authors: Jie Liu; Lei Wang; Judith Harvey-White; Douglas Osei-Hyiaman; Raj Razdan; Qian Gong; Andrew C Chan; Zhifeng Zhou; Bill X Huang; Hee-Yong Kim; George Kunos Journal: Proc Natl Acad Sci U S A Date: 2006-08-28 Impact factor: 11.205
Authors: B F Cravatt; K Demarest; M P Patricelli; M H Bracey; D K Giang; B R Martin; A H Lichtman Journal: Proc Natl Acad Sci U S A Date: 2001-07-24 Impact factor: 11.205
Authors: Joanne E Curran; Jeremy B M Jowett; Kate S Elliott; Yuan Gao; Kristi Gluschenko; Jianmin Wang; Dalia M Abel Azim; Guowen Cai; Michael C Mahaney; Anthony G Comuzzie; Thomas D Dyer; Ken R Walder; Paul Zimmet; Jean W MacCluer; Greg R Collier; Ahmed H Kissebah; John Blangero Journal: Nat Genet Date: 2005-10-09 Impact factor: 38.330
Authors: Paula Tejera; Nuala J Meyer; Feng Chen; Rui Feng; Yang Zhao; D Shane O'Mahony; Lin Li; Chau-Chyun Sheu; Rihong Zhai; Zhaoxi Wang; Li Su; Ed Bajwa; Amy M Ahasic; Peter F Clardy; Michelle N Gong; Angela J Frank; Paul N Lanken; B Taylor Thompson; Jason D Christie; Mark M Wurfel; Grant E O'Keefe; David C Christiani Journal: J Med Genet Date: 2012-10-09 Impact factor: 6.318
Authors: Georgia Balsevich; Martin Sticht; Nicole P Bowles; Arashdeep Singh; Tiffany T Y Lee; Zhiying Li; Prasanth K Chelikani; Francis S Lee; Stephanie L Borgland; Cecilia J Hillard; Bruce S McEwen; Matthew N Hill Journal: Proc Natl Acad Sci U S A Date: 2018-07-02 Impact factor: 11.205
Authors: Stephen D Turner; Richard L Berg; James G Linneman; Peggy L Peissig; Dana C Crawford; Joshua C Denny; Dan M Roden; Catherine A McCarty; Marylyn D Ritchie; Russell A Wilke Journal: PLoS One Date: 2011-05-11 Impact factor: 3.240
Authors: Qiping Feng; Lan Jiang; Richard L Berg; Melissa Antonik; Erin MacKinney; Jennifer Gunnell-Santoro; Catherine A McCarty; Russell A Wilke Journal: PLoS One Date: 2010-12-31 Impact factor: 3.240